Skip to content
lifestyle.brickvest.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Cumulus Neuroscience
NeuLogiq® Platform Helps Confirm No Evidence of Psychotomimetic, Hallucinatory, or Dissociative Effects in a Phase 1b Study of a Novel Neuroplastogen Developed for Major Depressive Disorder
May 28, 2026
Cumulus Neuroscience Appoints Ricardo Sáinz Fuertes, MD as New Board Chair
January 8, 2026
Cumulus Neuroscience Publishes Data Validating a Scalable Measurement of Neuroplasticity Using Low-Burden Dry Sensor EEG
January 6, 2026
Cumulus Neuroscience Presents Data at CTAD 2025 Annual Meeting
December 5, 2025